Biotage success in re-examination proceedings


– U.S. Court of Appeals for the Federal Circuit have affirmed US Patent and
Trademark Office’s Patent Trial and Appeal Board decisions to reject all claims
in US patents 7,138,061, 7,381,327 and 7,410,571.
A lawsuit was filed against Biotage by Scientific Plastic Products, Inc. (“SPP”)
concerning alleged infringement of the US patents no 7,138,061, 7,381,327 and
7,410,571. Biotage then filed requests with the US Patent and Trademark Office
for re-examination of all patent claims in the three patents mentioned above. At
the same time Biotage moved to stay the lawsuit in the district court pending
the outcome of the re-examination proceedings with the consent of SPP, and the
court stayed the district court lawsuit pending resolution of the reexamination
proceedings.

The US Patent and Trademark Office’s Patent Trial and Appeal Board affirmed the
Examiner’s decision to reject all claims of US patents 7,138,061, 7,381,327 and
7,410,571. SPP filed an appeal to the U.S. Court of Appeals for the Federal
Circuit. On September 10, 2014, the appeals court affirmed the rejections of all
claims.

“We have all the way believed that we have a strong position and that the
plaintiff did not have good cause for the alleged patent infringement. This
decision confirms our initial analysis of the legal situation.”, says Torben
Jørgensen, CEO, Biotage AB.

Contact:

Torben Jörgensen, President and CEO
Phone: +46 707-49 05 84, torben.jorgensen@biotage.com


Biotage discloses the information provided herein pursuant to the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The
information was submitted for publication at 2pm on 11 September 2014.


About Biotage
Biotage offers efficient separation technologies for use within analytical all
the way up to industrial scale as well as highly qualitative solutions for
analytical chemistry in research and at commercial analytical laboratories.
Biotage’s products are used by e.g. governmental authorities, academic
institutions, pharma and food industries. The company is headquartered in
Uppsala and has offices in the US, UK, China and Japan. Biotage has approx. 290
employees and had sales of 445 MSEK in 2013. Biotage is listed on the NASDAQ OMX
Nordic Stockholm stock exchange. Website: www.biotage.com

Attachments

09110377.pdf